<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921037</url>
  </required_header>
  <id_info>
    <org_study_id>EK Nr: 128/2006</org_study_id>
    <nct_id>NCT00921037</nct_id>
  </id_info>
  <brief_title>First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas</brief_title>
  <official_title>First Clinical Study of Erbium-YAG Laser Vaporisation of Cutaneous Neurofibromas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether multiple cutaneous neurofibromas in
      patients with neurofibromatosis type 1 can be removed with an erbium-YAG-laser.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With a prevalence of 1 in 3-5000 births, neurofibromatosis Type I is one of the most common
      genetic defects. The mode of inheritance is autosomal dominant and affects a gene (NF1),
      which is responsible for the production of the tumor suppressor protein neurofibromin. The
      consequence is an uninhibited expansion of neural tissue which leads amongst others to
      cosmetic disfigurement of the patients. In comparison to the plexiform neurofibromas the
      cutaneous tumors do not undergo malignant transformation.

      Excision and CO2 laser vaporisation were established as standard treatment but cause
      unattractive scars.

      In one operation more than 500 neurofibromas can be removed with an Erbium: YAG laser (2940
      nm). The tumors are dissected by shooting holes into the skin and vaporising the
      neurofibromas in-between or underneath. Specimen are harvested after Er: YAG-, CO2 - and
      electrosurgical treatment to evaluate the difference of thermal necrosis histologically and
      photographs are taken to assess the cosmetic results.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The aim of this study is to enhance the quality of life (measured by the Nottingham Health Profile the Rosenberg's Self-Esteem Scale and the SF-36 health survey) of patients suffering from disfigurement due to thousands of cutaneous neurofibromas.</measure>
    <time_frame>6 months</time_frame>
    <description>The standardized questionnaires are done before and 6 month after the operation in which the tight tumor cluster are phased down and thereby an almost normal skin appearance is achieved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>With this new method we want to decrease the painfulness, accelerated the time till wound healing as well as reduce the stay in hospital and the incidence of side effects.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Cutaneous Neurofibromas</condition>
  <arm_group>
    <arm_group_label>Erbium YAG Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Neurofibromatosis Type 1 (Recklinghausen)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Erbium-YAG laser vaporization</intervention_name>
    <description>spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequency of 6-12 Hz</description>
    <arm_group_label>Erbium YAG Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with multiple cutaneous neurofibromas with the request for tumor removal

        Exclusion Criteria:

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Happak, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Plastic and Reconstructive Surgery, Surgical Clinic, Medical University of Vienna, Austria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wolfgang Happak, Prof. MD</last_name>
    <phone>0043-1-40400</phone>
    <phone_ext>6980</phone_ext>
    <email>lukikriechbaumer@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lukas Kriechbaumer, MD</last_name>
    <phone>0043-650-8423766</phone>
    <email>lukasKriechbaumer@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Plastic and Reconstructive Surgery, Surgical Clinic, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Happak, Prof. MD</last_name>
      <phone>0043-1-40400</phone>
      <phone_ext>6980</phone_ext>
      <email>lukikriechbaumer@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Happak, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukas Kriechbaumer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Algermissen B, Müller U, Katalinic D, Berlien HP. Laserbehandlung von kutanen Neurofibromen. journalmed. 12; 2001.</citation>
  </reference>
  <reference>
    <citation>Becker DW Jr. Use of the carbon dioxide laser in treating multiple cutaneous neurofibromas. Ann Plast Surg. 1991 Jun;26(6):582-6.</citation>
    <PMID>1909107</PMID>
  </reference>
  <reference>
    <citation>Kardorff B. Neurofibromatose Typ I (Morbus Recklinghausen): Kombinierte Erbium.Yag-Laser- und Exzisionstherapie von kutanen Neurofibromen. Derm 1998; 4:404-406</citation>
  </reference>
  <reference>
    <citation>Moreno JC, Mathoret C, Lantieri L, Zeller J, Revuz J, Wolkenstein P. Carbon dioxide laser for removal of multiple cutaneous neurofibromas. Br J Dermatol. 2001 May;144(5):1096-8.</citation>
    <PMID>11359412</PMID>
  </reference>
  <reference>
    <citation>Ostertag JU, Theunissen CC, Neumann HA. Hypertrophic scars after therapy with CO2 laser for treatment of multiple cutaneous neurofibromas. Dermatol Surg. 2002 Mar;28(3):296-8.</citation>
    <PMID>11896787</PMID>
  </reference>
  <reference>
    <citation>Querings K, Fuchs D, Küng EE, Hafner J. [CO2-laser therapy of stigmatizing cutaneous lesions in tuberous sclerosis (Bourneville-Pringle) and in neurofibromatosis 1 (von Recklinghausen)]. Schweiz Med Wochenschr. 2000 Nov 11;130(45):1738-43. German.</citation>
    <PMID>11109606</PMID>
  </reference>
  <reference>
    <citation>Roenigk RK, Ratz JL. CO2 laser treatment of cutaneous neurofibromas. J Dermatol Surg Oncol. 1987 Feb;13(2):187-90.</citation>
    <PMID>3100595</PMID>
  </reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>July 11, 2011</last_update_submitted>
  <last_update_submitted_qc>July 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wolfgang Happak, Prof. MD</name_title>
    <organization>Division of Plastic and Reconstructive Surgery, Surgical Clinic, Medical University of Vienna, Austria</organization>
  </responsible_party>
  <keyword>Neurofibromatosis Type 1</keyword>
  <keyword>Morbus Recklinghausen</keyword>
  <keyword>cutaneous neurofibromas</keyword>
  <keyword>Erbium-YAG-Laser</keyword>
  <keyword>Vaporisation</keyword>
  <keyword>Thermal Necrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

